Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients.

We compared steady-state pharmacokinetics of mycophenolate mofetil (MMF) - Myfenax(®) (Teva) and CellCept(®) (Roche) - in stable kidney transplant recipients (KTRs). This was an international, multi-centre, randomized, open-label, two-treatment, two-sequence crossover study with a 3-month follow-up. We included KTRs at least 12 months post-transplantation with stable renal graft function for at least 3 months.

Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial.

The cost of immunosuppression following transplantation can be reduced by using generic ciclosporin (for example, Equoral) rather than innovator ciclosporin drugs such as Neoral. Thus, this study aims to evaluate the interchangeability, safety, and tolerability of Equoral, a generic ciclosporin, with Neoral in stable adult renal transplant recipients. This was a multicenter, randomized, open-label, parallel-group clinical trial in stable renal transplant patients, comparing 6 months of treatment with Equoral with the same treatment period on Neoral.

[Comparison of immunochemical and biochemical methods for determination of occult fecal blood].

The authors compared two tests of occult Fecal Blood Loss--the immunochemical Hemolex test based on agglutination of latex particles lined with antibodies against human haemoglobin and the biochemical Haemoccult test. Both tests were used to examine 55 patients invited to the department for endoscopic polypectomy or coloscopy as part of dispensarization after resection of colorectal carcinoma. The sensitivity of the Hemolex test (48.